Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Iovance Biotherapeutics (IOVA) Gets a Buy Rating from Chardan Capital
12:05pm, Wednesday, 29'th Apr 2020
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics (IOVA) today and set a price target of $44.00. The company's
Iovance Biotherapeutics (IOVA) Gets a Buy Rating from Chardan Capital
12:05pm, Wednesday, 29'th Apr 2020
Chardan Capital analyst
Geulah Livshits
reiterated a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) today and set a price target of
$44.00
. The company’s shares closed last Tues
CAMBRIDGE, Mass., April 28, 2020 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9.
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by BidaskClub
10:06am, Saturday, 25'th Apr 2020
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday, BidAskClub reports. Other research ana
Intellia Therapeutics (NASDAQ:NTLA) Upgraded to "Buy" at Zacks Investment Research
09:42am, Tuesday, 21'st Apr 2020
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Zacks.com reports. The firm currently has
Exelixis (EXEL) Received its Third Buy in a Row
02:32am, Tuesday, 21'st Apr 2020
After Piper Sandler and RBC Capital gave Exelixis (NASDAQ: EXEL) a Buy rating last month, the company received another Buy, this time from Oppenheimer.
Exelixis (EXEL) Received its Third Buy in a Row
02:32am, Tuesday, 21'st Apr 2020
After Piper Sandler and RBC Capital gave Exelixis (NASDAQ: EXEL) a Buy rating last month, the company received another Buy,
Oppenheimer Believes Seattle Genetics (SGEN) Won't Stop Here
01:46am, Monday, 20'th Apr 2020
Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Seattle Genetics (SGEN) yesterday and set a price target of $146.00. The company's shares
Oppenheimer Believes Seattle Genetics (NASDAQ: SGEN) Won’t Stop Here
01:46am, Monday, 20'th Apr 2020
Oppenheimer analyst Silvan Tuerkcan maintained a Buy rating on Seattle Genetics (SGEN – Research Report) yesterday and set a price
Intellia Therapeutics Inc (NASDAQ:NTLA) Stock Holdings Lifted by Bank of New York Mellon Corp
08:14am, Sunday, 19'th Apr 2020
Bank of New York Mellon Corp increased its holdings in Intellia Therapeutics Inc (NASDAQ:NTLA) by 4.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 223,967
Intellia Therapeutics Getting Closer To Key Technical Measure
07:00am, Friday, 17'th Apr 2020
A Relative Strength Rating upgrade for Intellia Therapeutics shows improving technical performance. Will it continue?
Intellia Therapeutics Inc (NASDAQ:NTLA) Given Consensus Recommendation of "Buy" by Brokerages
12:36pm, Thursday, 16'th Apr 2020
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) have been assigned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. F
Exchange Traded Concepts LLC Grows Stock Holdings in Intellia Therapeutics Inc (NASDAQ:NTLA)
10:14am, Thursday, 16'th Apr 2020
Exchange Traded Concepts LLC raised its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 98.8% during the first quarter, according to its most recent disclosure with the Securities & E
How Does Intellia Therapeutics, Inc. (NASDAQ:NTLA) Affect Your Portfolio Volatility?
04:00pm, Monday, 13'th Apr 2020
If you own shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) then it's worth thinking about how it contributes to...
UBS Asset Management Americas Inc. Sells 1,749 Shares of Intellia Therapeutics Inc (NASDAQ:NTLA)
10:52am, Monday, 13'th Apr 2020
UBS Asset Management Americas Inc. lessened its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with
